Illumina fights EU order to divest Grail
- ByFXEmpire-
By Foo Yun Chee BRUSSELS (Reuters) – U.S. life science company Illumina on Wednesday took its case to senior EU and national antitrust officials at a closed hearing to argue...
By Foo Yun Chee BRUSSELS (Reuters) – U.S. life science company Illumina on Wednesday took its case to senior EU and national antitrust officials at a closed hearing to argue...
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Wednesday, February 8th. Please refresh for updates. Chipotle (NYSE:CMG) stock fell 4.2% after the burrito...
By Geoffrey Smith Investing.com -- Joe Biden proposes quadrupling the tax on stock buybacks, in a State of the Union speech otherwise only notable for some political theater. Uber...
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
For the consumer, inflation losing its sharp edge was the story this week. It was a move fuelled mostly by a welcomed drop in gas prices. But for the investor, the positive...
Tech shares have mostly begun 2022 on a down note, as the tech-heavy NASDAQ 100 index has lost 5% since the start of the year. Seasoned investors realize that occasional market...
Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Core Illumina products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. GRAIL is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed for genetic analysis. Customers use its platforms to perform whole genome, de novo, exome and ribonucleic acid (RNA) sequencing, and targeted resequencing of specific gene regions and genes. The Company's BeadArray technology produces arrays that can perform many assays simultaneously. Customers use its array-based genotyping consumables for a range of analyses, including diverse species, disease-related mutations, and genetic characteristics associated with cancer.
| Average | 244.60 (+22.08% Upside) |
| High | 300.00 |
| Low | 150.00 |
| Price | 200.36 |
| No. of Analysts | 20 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Neutral | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 4.94 | 4.94 | 4.80 | +0.180 | +3.78% | 15.30M | Sydney | |||
| 195.23 | 195.745 | 191.55 | +4.900 | +2.57% | 849.29K | Sydney | |||
| 7.94 | 7.98 | 7.85 | +0.01 | +0.13% | 1.34M | Sydney | |||
| 0.021 | 0.022 | 0.021 | -0.002 | -8.70% | 1.25M | Sydney | |||
| 0.049 | 0.049 | 0.049 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 0.355 | 0.355 | 0.355 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 0.49 | 0.49 | 0.485 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 16.70 | 16.83 | 16.45 | -0.570 | -3.30% | 5.06M | Sydney | |||
| 25.79 | 25.98 | 25.72 | +0.130 | +0.51% | 5.19M | Sydney | |||
| 28.40 | 28.48 | 27.80 | +0.22 | +0.78% | 273.60K | Sydney | |||
| 0.045 | 0.046 | 0.044 | +0.001 | +2.27% | 5.46M | Sydney | |||
| 0.021 | 0.021 | 0.019 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 0.022 | 0.023 | 0.022 | 0.00 | 0.00% | 837.47K | Sydney | |||
| 1.18 | 1.185 | 1.16 | +0.005 | +0.43% | 1.50M | Sydney | |||
| 0.74 | 0.76 | 0.725 | +0.015 | +2.07% | 131.16K | Sydney |